{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:43:02Z","timestamp":1785404582200,"version":"3.56.0"},"reference-count":31,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Noncommunicable Chronic Diseases\u2014National Science and Technology Major Project","award":["2024ZD0532000"],"award-info":[{"award-number":["2024ZD0532000"]}]},{"name":"Noncommunicable Chronic Diseases\u2014National Science and Technology Major Project","award":["2024ZD0532003"],"award-info":[{"award-number":["2024ZD0532003"]}]},{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People\u2019s Republic of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/04bdenw41","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objective: We aimed to quantify the prognostic value of glucose monitoring-derived time in range (TIR), including continuous glucose monitoring (CGM), flash glucose monitoring (FGM), and fingertip capillary glucose monitoring (FCGM), for predicting adverse clinical outcomes in patients with type 2 diabetes mellitus (T2DM). Research Design and Methods: PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL, via OVID) were systematically searched from 2017 to November 2025 for studies evaluating the risk of all clinically relevant outcomes associated with different TIRs in T2DM. Extracted data were standardized to evaluate the effect of a 10% increment in TIR. Pooled estimates were calculated using inverse-variance random-effects models incorporating dose\u2013response analysis. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework. Results: Twenty-four observational studies involving 20 distinct associations and 35,916 participants were included. Dose\u2013response meta-analyses were conducted for nine associations. The results showed that each 10% increment in TIR was significantly associated with a reduced risk of multiple adverse complications, including all-cause mortality (odd ratio [OR] = 0.88, 95% confidence interval [CI]: 0.82\u20130.93), vision-threatening diabetic retinopathy (OR = 0.93, 95% CI: 0.87\u20130.98), diabetic retinopathy (OR = 0.92, 95% CI: 0.89\u20130.95), lower extremity atherosclerotic disease (OR = 0.86, 95% CI: 0.82\u20130.91), diabetic peripheral neuropathy (OR = 0.77, 95% CI: 0.71\u20130.84), and cardiovascular autonomic neuropathy (OR = 0.81, 95% CI: 0.68\u20130.97). In contrast, the associations for albuminuria (KDIGO [Kidney Disease: Improving Global Outcomes] A2 and A3) and amputation did not reach statistical significance in the primary meta-analysis. Conclusions: In conclusion, each 10% increment in TIR is consistently associated with a reduced risk of mortality and various micro- and macrovascular complications in T2DM. These findings suggest TIR as a robust prognostic indicator and actionable therapeutic target in diabetes management.<\/jats:p>","DOI":"10.3390\/jcm15145713","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:35:52Z","timestamp":1784630152000},"page":"5713","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Time in Range and Adverse Outcomes in Type 2 Diabetes: A Quantitative Synthesis"],"prefix":"10.3390","volume":"15","author":[{"given":"Furong","family":"Qu","sequence":"first","affiliation":[{"name":"General Practice Ward\/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu 610000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, West China Hospital, Sichuan University, Chengdu 610000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyue","family":"Zeng","sequence":"additional","affiliation":[{"name":"General Practice Ward\/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu 610000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1365-3620","authenticated-orcid":false,"given":"Zhipeng","family":"Li","sequence":"additional","affiliation":[{"name":"General Practice Ward\/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu 610000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5381-4716","authenticated-orcid":false,"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"(2024). Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care, 47, S179\u2013S218.","DOI":"10.2337\/dc24-S010"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"(2024). Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 105, S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2337\/dc18-1444","article-title":"Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials","volume":"42","author":"Beck","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1097\/CM9.0000000000002073","article-title":"Visit-to-visit glycated hemoglobin A1c variability in adults with type 2 diabetes: A systematic review and meta-analysis","volume":"135","author":"Qu","year":"2022","journal-title":"Chin. Med. J. (Engl.)"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Huang, H., Yan, X., Hapca, S., Bell, S., Qu, F., Liu, L., Chen, X., Zhang, S., and Shi, Q. (2022). Glycated Haemoglobin A1c Variability Score Elicits Kidney Function Decline in Chinese People Living with Type 2 Diabetes. J. Clin. Med., 11.","DOI":"10.3390\/jcm11226692"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2337\/dc19-0823","article-title":"Visit-to-Visit HbA(1c) Variability Is Associated With Cardiovascular Disease and Microvas-cular Complications in Patients With Newly Diagnosed Type 2 Diabetes","volume":"43","author":"Li","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/jdi.13336","article-title":"Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications study","volume":"12","author":"Kuroda","year":"2021","journal-title":"J. Diabetes Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e2221","DOI":"10.1210\/clinem\/dgac034","article-title":"Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring","volume":"107","author":"Yapanis","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2337\/dc17-1600","article-title":"International Consensus on Use of Continuous Glucose Monitoring","volume":"40","author":"Danne","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.2337\/dc18-1131","article-title":"Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes","volume":"41","author":"Lu","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1089\/dia.2019.0499","article-title":"Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes","volume":"22","author":"Yoo","year":"2020","journal-title":"Diabetes Technol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.2337\/dc20-0909","article-title":"Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor-Augmented Insulin Pump-Treated Type 1 Diabetes","volume":"43","author":"Ranjan","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/biom.13197","article-title":"Optimal approximate conversions of odds ratios and hazard ratios to risk ratios","volume":"76","author":"VanderWeele","year":"2020","journal-title":"Biometrics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res. Synth. Methods"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.21037\/atm.2017.06.43","article-title":"The evidence system of traditional Chinese medicine based on the Grades of Recommenda-tions Assessment, Development and Evaluation framework","volume":"5","author":"Chen","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.taap.2006.01.003","article-title":"Diabetes and mitochondrial function: Role of hyperglycemia and oxidative stress","volume":"212","author":"Rolo","year":"2006","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1479164111421033","article-title":"Fluctuating hyperglycaemia increases oxidative stress response in lean rats compared to sustained hyperglycaemia despite lower glycaemic exposure","volume":"8","author":"Rakipovski","year":"2011","journal-title":"Diab Vasc. Dis. Res."},{"key":"ref_24","first-page":"5647219","article-title":"A Protective Role of Paeoniflorin in Fluctuant Hyperglycemia-Induced Vascular Endothelial Injuries through Antioxidative and Anti-Inflammatory Effects and Reduction of PKC\u03b21","volume":"2019","author":"Wang","year":"2019","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2337\/dc20-1862","article-title":"Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study","volume":"44","author":"Lu","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2337\/dci20-0066","article-title":"The Prognostic Value of Time in Range in Type 2 Diabetes","volume":"44","author":"Selvin","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e002573","DOI":"10.1136\/bmjdrc-2021-002573","article-title":"Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: A systematic review","volume":"10","author":"Raj","year":"2022","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1089\/dia.2022.0447","article-title":"Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE","volume":"25","author":"Bergenstal","year":"2023","journal-title":"Diabetes Technol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/CM9.0000000000001914","article-title":"Negative association of time in range and urinary albumin excretion rate in patients with type 2 diabetes mellitus: A retrospective study of inpatients","volume":"135","author":"Chai","year":"2022","journal-title":"Chin. Med. J. (Engl.)"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e3498","DOI":"10.1002\/dmrr.3498","article-title":"Time in range in relation to amputation and all-cause mortality in hospitalised patients with diabetic foot ulcers","volume":"38","author":"Xie","year":"2022","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"20420188221099337","DOI":"10.1177\/20420188221099337","article-title":"Association of continuous glucose monitoring-derived time in range with major amputation risk in diabetic foot osteomyelitis patients undergoing amputation","volume":"13","author":"Yin","year":"2022","journal-title":"Ther. Adv. Endocrinol. Metab."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5713\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:30:08Z","timestamp":1784781008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":31,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145713"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145713","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}